Mechanism of Action
BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murine leukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of the assays,…
Indications (6)
Clinical Trials (5)
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease
A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia
A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia
Loss of Exclusivity
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8501760 | Jul 18, 2026 | Product | — |
| 8389537 | Jul 18, 2026 | U-1374 | |
| 8415363 | Jul 18, 2026 | SubstanceProduct | U-1374 |
| 8415363*PED | Jan 18, 2027 | — | |
| 8389537*PED | Jan 18, 2027 | — |